Zydus Lifesciences to launch generic semaglutide injection for weight loss, diabetes after Ozempic’s patent expiry
Published on: Feb. 26, 2026, 3:09 p.m. | Source: The Financial Express
Zydus Lifesciences will launch generic semaglutide injections in India following patent expiry, after receiving approval from the Drug Controller General of India. The company plans branded launches with an innovative reusable, adjustable single-pen device aimed at improving adherence and lowering obesity and diabetes treatment costs.
